Book Online Consultation

Contact Details

051-2287730, 2287720

[email protected]

9-Kaghan Road, F8/3, Islamabad

www.profgill.com

Education

  • MBBS, Nishtar Medical College, Multan, Pakistan. 1979 – 1985
  • Diplomat, American board of Internal Medicine in August 1997
  • Diplomat, American board of Gastroenterology and Hepatology Nov 2002.
  • Master of Science in clinical research, university of Minnesota, Minneapolis, Minnesota U.S.A 1998 – 2000.

Professor Muzzaffar Lateef Gill

(Sitara–i–Imtiaz)

M.D (USA) MS (USA), FACG

Diplomat American Board of Internal Medicine

Diplomat American Board of Gastroenterology

Professor of Medicine and Gastroenterology

Professor of Medicine, Fazaia Medical College, Islamabad

C.E.O: Islamabad Gastroenterology Associates

Career Profile

  • Professor Of Medicine Fazaia Medical College, Islamabad since January 1st 2019.
  • Consultant Gastroenterologist/ Hepatologist at Pakistan Air force Hospital Oct 1st 2018.
  • Chief Department of Medicine Maroof international hospital Islamabad from June 2009 to Dec 2017.
  • Consultant Gastroenterologist/Hepatologist, Islamabad Specialists Clinic Islamabad November 2007 to Feb 2009.
  • Consultant Gastroenterologist / Hepatologist, Shifa international hospital, Islamabad. May 2002 – October 2007.
  • Professor of Medicine Shifa College of medicine Islamabad-Pakistan May 2002 to October 2007.
  • Staff physician gastroenterology section, department of veteran’s affairs, St- Cloud, MN 56303, USA, July 2000 – May 2002.
  • Assistant Professor of medicine, university of Minnesota Medical School, July 1997 to June 2002.
  • Consultant Physician embassies of USA, UK Switzerland and, Saudi Arabia, Islamabad Pakistan from March 2003.

Post Graduate Training

  • House officer / Registrar, department of internal medicine, Nishtar hospital, Multan, Pakistan July 1985 – Dec 1987.
  • Postgraduate study in internal medicine, Edinburgh post graduate board for medicine United Kingdom Jan 1988 – Dec 1988.
  • Registrar in internal medicine, Western general hospital Edinburgh, United Kingdom Jan 1989 – Dec 1991.
  • Clinical research fellow, Western general hospital Jan1992 – Dec 1993.
  • Internal medicine residency, Hennepin county medical center Minneapolis, Minnesota Oct1994 – Jun 1997.
  • Fellowship in Gastroenterology / Hepatology, university of Minnesota U.S.A July 1997- June 2000.

Professional Memberships

  • Fellow American college of gastroenterology since 1997
  • Member Asian Pacific Association of study of liver disease since  July 2004
  • Member European Association of study of liver disease since July 2005.

Honors and Awards

  • Stara-i-Imatiaz, conferred upon by the president of Pakistan, in recognition of outstanding contribution in the field of medicine. August 14, 2006. This is the second highest civilian award of the country.
  • “Pride of Nishtar” presented by Nishtar  Alumni association December 2010, Nishtar Medical College Multan, Pakistan
  • Sarwar Jehan Zubari Gold Medal in Hepatology by the Pakistan society of gastroenterology / Hepatology March 2007, Karachi.
  • Khawaja Sadiq Hassan Gold Medal, Pakistan society of Gastroenterology, 2005.
  • Sarwar Jehan Zubari Gold Medal, Pakistan society of Gastroenterology, 2003.
  • Best Resident teacher Award, university of Minnesota, Academic Years 1996 – 1997.
  • Distinction and merit Award in Physiology, 1982.

Publications / Abstracts

  1. Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. 2015. Polymorphism ofthe IL28B gene (rs8099917, rs12979860)and virological response of Pakistani hepatitis C virusgenotype 3 patients to pegylated interferon therapy. Int J Infect Dis. 30:91-7.
  2. Aziz H, Aziz M, Gill ML. Analysis of Host and ViralRelated Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients. Viral Immunol. 31(3):256-263. I F: 1.53
  3. Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis BPatients. Viral Immunol. 2018 Oct 4. doi: 10.1089/vim.2018.0022
  4. Outcomes of Endoscopic Retrograde Cholangiopancreatography in Patients with Cirrhosis – Sidra Gill, Nosheen Y, Ammara N, Rabbea N, Muzzaffar G. – EASL 2016, 13th March - 17th March, 2016, Barcelona, Spain
  5. Outcomes of Endoscopic Retrograde Cholangiopancreatography in Patients with Cirrhosis – Sidra Gill, Nosheen Y, Ammara N, Rabbea N, Muzzaffar G. – 20th FEB -24th FEB, 2016, 25th APASL, Tokyo, Japan
  6. Outcomes of Sof and Riba Therapy for Hep C G3 Patients who are Relapsers of Peg Inf and Riba – Sidra Gill, Nosheen Y, Faiza I, Ammara N, Uzma F. Q. Muzzaffar G. –  20th  Feb - 24th  Feb, 2016, 25th APASL, Tokyo Japan
  7. Outcomes of Sof, Riba and Peg - Inf Therapy for the Treatment of Chronic Hep-C G3 Treatment Naive Patients – Sidra Gill, Nosheen Y, Faiza I, Ammara N, Uzma F. Q, Muzzaffar G. – 20th  Feb - 24th  Feb, 2016, 25th APASL, Tokyo Japan
  8. Outcomes of Sofosbuvir and Ribavirin for the Treatment of Hcv Recurrence After Liver Transplantation – Sidra Gill, Nosheen Y, Ammara N, Rabbea N Muzzaffar G. – 20th  Feb - 24th  Feb, 2016, 25th APASL, Tokyo Japan
  9. Outcomes of Sof and Riba Therapy for Hep C G3 Patients who are Relapsers of Peg Inf and Riba –Sidra Gill, Misbah M, Nosheen Y, Faiza I, Ammara N Muzzaffar G. – 3rd April - 5th April, 2015, 31st PSG, Islamabad, Pakistan
  10. Outcomes of Therapeutic Response To Tenofovir Dipivoxil Fumarate (TDF) in Chronic Hepatitis B Pregnant Patients – Sidra Gill, Ammara N, Misbah M, Faiza I, Muzzaffar G. – 12th March to 15th March, 2015, 24th APASL, Istanbul, Turkey
  11. Long Term Outcomes of Entecavir and Tenofovir Combination Therapy for Chronic Hepatitis B Patients With Previous Nucleos(t)ide Treatment Failure - Sidra Gill, Ammara N, Misbah M, Faiza I, Hafsa A, Muzzaffar Gill. – 12th March to 15th March, 2015, 24th APASL, Istanbul, Turkey
  12. Elevated Serum Levels of ALT are Associated With Metabolic Syndrome Independent of Fatty Liver Diagnosed By Ultrasound – Sidra G, Ammara N, Misbah M, Faiza I, Muzzaffar G. – 12th March to 15th March, 2015, 24th APASL, Istanbul, Turkey
  13. Outcomes of Rifaximin plus Lactulose versus Lactulose Alone in Treatment of Overt Hepatic Encephlopathy – Muzzaffar Lateef. Gill, T. Niaz, H. Aziz, S. Khan – 49th EASL,  9th April – 13th April, 2014, London, UK
  14. Outcomes of Rifaximin Plus Lactulose Versus Lactulose Alone in Treatment of Overt Hepatic Encephlopathy – Muzzaffar Lateef. Gill, T. Niaz, H. Aziz, S. Khan  – APASL 13th March - 16th March, 2014, Brisbane, Australia
  15. Nafld Is Predictor of Type 2 Diabetes & Prediabetes , A Prospective 5 Year Study – Uzma M. G, Hafsa A, Farah S, Muzaffar Gill  – GASTRO 2013 APDW -  21st SEP – 24th SEP, 2013, Shanghai, China
  16. Long Term Outcomes of Tenofovir (Tdf) Therapy in Treatment Naive Chronic Hepatitis B Patients – Uzma G, Hafsa A, Neelum A, Farah S. Muzaffar Gill – GASTRO 2013 APDW -  21st SEP – 24th SEP, 2013, Shanghai, China
  17. Long term Outcomes of Entecavir Therapy in treatment naive Chronic Hepatitis B patients - Uzma M. G, Hafsa A, Farah S, Muzaffar Gill – GASTRO 2013 APDW -  21st SEP – 24th SEP, 2013, Shanghai, China
  18. Prevalence & Clinical implications of occult HBV infection in patients with chronic HCV Infection – Uzma G, Hafsa A, Neelum A, Farah S. Muzaffar Gill – GASTRO 2013 APDW -  21st SEP – 24th SEP, 2013, Shanghai, China
  19. Treatment Outcomes of Acute Viral Hepatitis C, G 3 Patients with Peg-IFN -Alpha 2b Monotherapy versus Peg-IFN/ Ribavirin Combination – Uzma M. G, Hafsa A, Neelum A, Farah S, Muzaffar L. G. – APDW 2012, 5th DEC – 8th DEC 2012, Bangkok, Thailand
  20. Outcomes of Entecavir (Etv) and Tenofovir (Tdf) Combination Therapy in Chronic Hep-B Patients With Previous Treatment Failure – Uzma M. G, Neelum A, Farah S, Muzaffar L. G– 18th April – 22nd April, 2012, EASL ILC 2012, Barcelona, Spain
  21. Entecavir and Tenofovir Combination Therapy in Chronic Hepatitis B Patients – Muzzaffar Gill et al – 28th PSG & GI E - 1st March - 3rd March 2012, Karachi, Pakistan
  22. Efficacy of Tenofovir (Tdf) Treatment in Chronic Hepatitis B Patients With Suboptimal Response To Adefovir (Adv) – Muzaffar L. G; Mehmood, N; Salman, F; Anwar, N; Uzma G. – APDW 2011, 1st  Oct - 4th Oct, 2011, Singapore, Malaysia
  23. Risk Factors for Post ERCP Pancreatitis a Prospective Study - APDW 2011, – APDW 2011, 1st  Oct - 4th Oct, 2011, Singapore, Malaysia
  24. Outcomes of Entecavir (Etv) and Tenofovir (Tdf) Combination Therapy in Chronic Hep-B Patients With Previous Treatment Failure – Muzaffar L. G., Mehmood, N; Salman, F, Anwar, N, Gill, U – APDW 2011, 1st Oct - 4th Oct, 2011, Singapore, Malaysia
  25. Outcomes of Primary Prophylaxis of Gastric Variceal Bleeding Comparing Cyanoacrylate Injection With Beta Blockers Failure – Muzzaffar Gill, N Mehmood, Farah S, Neelum A, Uzma G. – APDW 2011, 1st Oct - 4th Oct, 2011, Singapore, Malaysia
  26. Outcomes of Entecavir (Etv) and Tenofovir (Tdf) combination therapy in chronic hep-B patients with previous treatment failure - Muzzaffar Gill, N Mehmood, Farah S, Neelum A, Uzma G. – APDW 2011, 1st Oct - 4th Oct, 2011, Singapore, Malaysia
  27. Virological Relapse Rate After Treatment Induced HBE Antigen Seroconversion in Chronic Hepatitis B (Chb) Patients – Muzaffar G, U. Adeeb, S. Naseem – 46th EASL , 30th Mar - 3rd Apr, 2011, Berlin, Germany
  28. Efficacy of Tenofovir (TDF) Treatment in Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (ADV) – M Gill, N Mehmood, F Salman, N Anwar, U Gill – 21st APSAL, 17th Feb – 20th Feb 2011, Bangkok, Thailand
  29. Long Term Outcomes of Entacavir Therapy for Chronic Hep B Patients – Muzzaffar Gill et al – 21st APSAL, 17th Feb – 20th Feb 2011, Bangkok, Thailand
  30. Outcomes of INF and Riba Therapy for Hep C G3 Patients who Relapsed with Previous Peg INF and Riba Therapy – Uzma A, Sajida N, Muzzaffar Gill – 21st APSAL, 17th Feb – 20th Feb 2011, Bangkok, Thailand
  31. Treatment Outcomes of Gastric (Fundus) Variceal Bleed by Endoscopic Sclerotherapy with N-Butyl-2 –Cyanoacrylate – Muzzaffar Gill et al – 21st APSAL, 17th Feb – 20th Feb 2011, Bangkok, Thailand
  32. Long Term Outcomes of Chronic Hep-C G3 Patients Treated With Peg Interferon and Ribavirin – Aqifa A, Saima F, Nasir K, Muzzaffar Gill – UEGW Barcelona 2010, 23rd Oct - 27th Oct, 2010, Barcelona, Spain
  33. Rapid Virological Response Is A Predictor of Sustained Virological Response in Chronic Hep C G3 Patients Treated With Pegasys and Rbv – U. Adeeb, F. Khattak, M.L. Gill – EASL,  14th Apr – 18th Apr, 2010, Vienna, Austria
  34. Preditors of outcomes after biliary and pancreatic sphincterotomy for sphinctor of oddi dysfunction - Martin Freeman, Muzzaffar Gill, Carol Overby, Journal of clinical gastroenterology 2007, Volume 41, issue 1, page 94-102.
  35. Treatment outcomes of Hep C G3 patients with Pegasys and Ribavirin vs. peg-intron / Ribavirin - Gill Muzaffar, Firdoos S, Sattar S, Ali Y, - 17th APASL 27th Mar – 30th Mar, 2007, Kyoto, Japan.
  36. Treatment outcomes of Hep C G3 patients with reduced dose of Peg-Interferon and Ribavirin, Gill Muzaffar, Fardoos S, Sattar S, Shah T.A, 17th APASL 27th Mar – 30th Mar, 2007, Kyoto, Japan.
  37. Outcomes of treatment of Hep C G3 Patients with thrice weekly standard interferon and Ribavirin, Gill Muzaffar, Firdoos S, Butt N, Amin A, and N. Khokhar, 17th APASL 27th Mar – 30th Mar, 2007, Kyoto, Japan.
  38. Efficacy o9f peg-interferon alfa 2a / Ribavirin treatment in Hep C G3 relapsers with standard Interferon / Ribavirin, Gill Muzaffar, Firdoos S, sattar S, N Khokhar, 17th APASL 27th Mar – 30th Mar, 2007, Kyoto, Japan
  39. Outcomes of peg-interferon Alfa 2b / Ribavirin treatment in Hep C G3 younger vs. older patients - Gill Muzaffar, Firdoos S, Sattar S, Shah T.A - 17th APASL 27th Mar – 30th Mar, 2007, Kyoto, Japan
  40. Treatment outcomes of Hepc Genotype 3 patients with Pegasys / Ribavirin without rapid Virological response - Gill Muzaffar, Firdoos S, Sattar S, N Butt, Adeeb U, Shah T.A- 4th international symposium on Hep C -  9th Sep -13th Sep 2007, Glasgow, Scotland
  41. Longterm outcomes of HEP C G3 patients who had svrrr after 6 months of treatment with peg-intron and ribavirin - Gill Muzaffar ,Firdoos S, N Butt, Khokhar N - 4th international symposium on HEP C 9th Sep - 13th Sep 2007, Glasgow, Scotland
  42. Treatment outcomes of hepC genotype 3 patients with pegasays, ribavirin without rapid virological response - Gill Muzaffar , Firdoos S,Butt N, Adeeb U, Shah TA -
    4th international symposium on HEP C 9th Sep - 13th Sep 2007, Glasgow, Scotland
  43. Long term outcomes of Hep C G3 patients who had SVR after 6 months of treatment with peg-interferon and Ribavirin - Gill Muzaffar, Firdoos S, N Butt, Khokhar N -
    4th international symposium on HEP C 9th Sep - 13th Sep 2007, Glasgow, Scotland
  44. Role of adjuvant therapy with erythropoietin and GCSF to improve sustained Virological response in chronic Hep C patients receiving Peg-Intron and Ribavirin - Gill Muzaffar, Firdoos S, Butt N, Adeeb U, Shah T.A - GUT 2007: 56(suppl III).
  45. Outcomes of terlipressin and albumin versus albumin in patients with cirrhosis and hepatorenal syndrome - Gill Muzaffar, Firdoos S, sattar S, N Butt, N Khokhar, - GUT 2007: (suppl III).
  46. Triple regime therapy for chronic Hepatitis – C patients - Khokhar N, Gill Muzaffar - Journal of Gastro-Hepatol. December 2004.
  47. Psychological impact of Hepatitis – C diagnosis in Pakistani population - Gill Muzaffar, Atiq M, Sattar S, Tauqir A. Shah - Journal of Gastro-Hepatol, December 2004.
  48. Treatment outcomes of chronic Hepatitis – C patents with normal ALT with Pegylated interferon - Gill Muzaffar, Atiq M, Sattar S, Nasir, Khokhar - Journal Gastro-Hepatol December 2004.
  49. Lamuvidine treatment for chronic Hepatitis B - Gill Muzaffar, Khokhar N, Ali Yawar Alam - JCPSP 2005 Vol 15 (2) 78:80.
  50. Physiological impact of HCV diagnosis - Gill Muzaffar, Atiq M, Sattar S - Journal of Gastro – Hepatol 2005, 11 200 – 205.
  51. Treatment outcomes with long acting octreotide in inoperable Hepatocellular carcinoma - Gill Muzaffar, Atiq M, and Khokhar N - J Pak Medical Association, 500 – 503 JPMA 2005.
  52. Achalasia dilatation without fluoroscopy - Khokhar N, Gill Muzaffar - 330 - 334, JPMA 2004.
  53. Outcomes of triple therapies for hepatitis – C patients, Pakistani experience - Gill Muzaffar, Khokhar N - Journal of Gastro – Hepatol, December 2004.
  54. General Seroprevalence of Hepatitis – C and Hepatitis – B virus Infections in Pakistani population - Gill Muazffar, khakhar N, Malik Gj. - JCPSP 2004; 14:534 – 538.
  55. Non endoscopic parameters for the Identification of esophageal varices in patient with cirrhosis: a cross-sectional study and literature review - Gill Muzaffar, Atiq m, Sattar S, khokhar N - J Pak Med Association 2004. 11, 575 – 577.
  56. NSAID induced gastro intestinal injury - Khokhar N Gill Muzaffar. - Rawal medical journal 2003:28; 22 – 24.
  57. Quality of life assessment in Pakistani patients with chronic liver disease - Atiq M, Gill Muzaffar. Khokhar N - J Pak medical Assoc 2004; 54:113 – 115.
  58. Small bowel vascular insufficiency presenting as abdominal pain - Atiq M, Gill Muzaffar. Khokhar N - Rawal medical J 2004; 29: 42 – 43.
  59. Serological profile of incidentally detected asymptomatic HBs Ag positive subjects - Khokhar N, Gill Muzaffar - (IDAHS) JPMA 2004; 14:16-18.
  60. Tropical sprue in Pakistan - Khokhar N, Gill Muzaffar - J Pak medical Assoc 2004; 54:135.
  61. Serological profile of incidentally detected asymptomatic Hep B surface Ag positive subjects - Khokhar N, Gill Muzaffar - (IDAHS) JPMA 2004; 14:16 – 18.
  62. Spectrum of Hepatocellular carcinoma - Khokhar N, Aijazi I, Gill Muzaffar - at shifa International hospital, Islambad. J. Ayub medical coll abbottabad 2003; 15:1 – 4.
  63. Esophageal stricture in a tertiary care center - Khokhar N, Gill Muzaffar, Khan MM. - J coll physician’s surgical Pak 2003; 14”553 – 555.
  64. Long-action calcium channel blocker in renal impairment patients. Nephrology dialysis and transplantation - Gill Muzaffar, JL anderton, ALP Notghi - 7, 701 – 708, 1994.
  65. Renal Homodynamic effects of bunazosin retard and Prazosin in mild to moderately hypertensive patients with normal or moderately impaired renal function. Nephrology, dialysis and transplantation - Anderton JL, Gill Muzaffar, Notghi A. - 9:607 – 612, 1994.
  66. Erythropoietin – Induced hypertension without raising hematocrit. Nephrology, dialysis and transplantation - Gill Muzaffar, Anderton JL - 3: 1264 – 1266, 1993.

National Lectures

  1. Treatment of Chronic Hepatitis C genotype i patients, March 3rd 2012 28th annual meeting of Pakistan society of gastroenterology in Karachi.
  2. Invited lecture, Pakistan medical association Jhelum march 22 2012. treatment challenges of chronic hepatitis C.
  3. Invited lecture, Pakistan society of family physicians, Rawalpindi/Islamabad Chapter "Treatment challenges of chronic hepatitis C in Pakistan" April 14th 2011
  4. Invited lecture, Pakistan society of gastroenterology annual conference, foundation university Rawalpindi "Functional bowel disorders" March 20th 2011
  5. Invited lecture, Pakistan medical association, Jehlum chapter "Paradigm shift in Hepatitis C treatment" March 3rd 2011
  6. Invited lecture, Nishtar medical college alumni association N-28 Silver jublee "Chronic hepatitis C treatment" Dec 24th 2010
  7. Invited lecture on primary prevention of variceal bleed, Pakistan society for study of liver diseases (PSSLD), April 4th 2010, Rawalpindi, Pakistan.
  8. Invited Sate of the art Lecture on Hepatitis – B & C confection on July 25 – 26, 2009. Society of Gastroentology and Hepatology Faisalabad, Pakistan.
  9. Invited State of the art lecture on Management of Chronic Hepatitis B, PSSLD single topic conference April 12 2009 in Rawalpindi.
  10. Invited State of the art lecture, Management of Hepatitis C, Annual Conference of (PSSLD), November 2007 Karachi.
  11. Invited State of the art lecture, annual conference of Pakistan Society for study of liver diseases (PSSLD) Management of portal hypertension July 28, 2007 Karachi.
  12. Invited State of Art Lecture, in Pakistan Society of Gastroenterology Annual Conference in Karachi, March 2nd Title: “Hepatitis C Genotype IV Pakistani Perspectives”. Hepatitis C.
  13. Invited State of the Art Lecture, Annual Meeting of Pakistan Society of Gastroenterology, Hepatitis C. new avenues of Treatment, Mar 25, 2005.
  14. Invited Lecture Pakistan Institute of Medical Sciences (PIMS) Indication/Contra indication of Liver Transplantation, Mar 05,2005
  15. Invited Lecture Aga Khan University Hospital Karachi, Hepto-Renal Syndrome Mar 01, 2005.
  16. Invited Lecture, King Edward, Medical College, New Avenues of Treatment of Irritable bowel syndrome Feb 28, 2005
  17. Invited Lecture, Controversies, Asia Pacific Association of Study of Liver New Delhi India. Challenge in hepatitis C therapy, Dec 2004
  18. Invited Lecture, Asia Pacific Association of Study of Liver New Delhi India, Hepatitis C Treatment in Relapsers and on-responders, Dec 2004.
  19. Invited State of the Art Lecture Pakistan Society of Hepatology, a) Treatment of Hepatocellular Carcinoma. b) Management of Hepatitis B, Oct 2004.
  20. Invited Lecture, International Society of Quality of life research, Hong Kong meeting, Psychological impact of Hepatitis C Diagnosis, September 25, 2004.
  21. Invited State of the art lecture Pakistan society of Hepatology.
    • a) Treatment of Hepatocellular carcinoma.
    • b) Management of Hepatitis – B, Oct 2004.
  22. Invited State of the art lecture 19th annual congress of Pakistan, Society of Gastroenterology, and a) Variceal Bleed Management.
  23. b) New Avenues of treatment Irritable Bowl Syndrome.
  24. c) New Avenues of treatment of Hepatitis – C Feb 30, 2004.
  25. Invited Lecture at KRL Hospital Islamabad, Hepatitis – C management June 07, 2004.
  26. Invited Lecture Ayub medical college, Abbottabad, controversies and challenges in Hepatitis – C treatment, May 05, 2004.
  27. Invited State of the art lecture infectious disease society of Pakistan Ayub medical college, Abbottabad, controversies and challenges in Hepatitis – C treatment, March 2004.
  28. Invited State of the art lecture Quaid – e – Azam Medical College Bahawalpur, Management of chronic Hepatitis – B. Feb 2004.
  29. Pakistan Society of oncology annual meeting, Hepatocelluler carcinoma treatment challenges, Dec 2003.
  30. Pakistan Society of Gastroenterology Annual Meeting, current treatment challenges of Hepatitis – C, June 15, 2003.
  31. Nishtar Medical College Multan, Pakistan state of the art lecture. NSAID induced Gastropathy May 11, 2003.
  32. Annual scientific conference, upper GI Bleed an update, May 5, 2003.
  33. Annual scientific conference of Pakistan medical association state of the art lectures At Rawalpindi H-Pylori ulcer and beyond May 04, 2003.
  34. Invited Lecture Pakistan Islamic Medical Association (PIMA) Annual Conference in Rawalpindi, Hepatitis – B up date, April 30, 2003.
  35. Annual scientific session of Pakistan society of surgeons, state of the art Lecture. Hepatocellular CA treatment Feb 22, 2003.
  36. Annual scientific session of Pakistan society of surgeons, lecture, Role of ERCP in Malignant obstructive Jaundice Feb 21, 2003.
  37. 348th annual scientific conference of Pakistan medical association, Controversies / challenges of Hepatitis C treatment, Dec 27, 2002.

International Lectures

  1. Invited Lecture on treatment of Hepatitis – C relapsers and non responders, 6th APASL single topic conference, Dec 10 – 12, 2009. Karachi, Pakistan.
  2. Invited state of the art lecture on Management of Hepatorenal syndrome by (UEGW) United European Gastroenterology week, Paris France October 22 2008.
  3. Invited state of the art lecture on Hepatitis C Treatment with Pegylated interferon, ), Asia pacific association of study of liver diseases (APASL)  Kyoto, Japan March 22, 2007.
  4. Invited Lecture by UEGW 2006 Berlin Germany, October 2006. Title: “Hepatitis C Asian Perspectives”.
  5. Invited lecture by International Symposium on Viral Hepatitis, Paris, France July 2, 2006. Tetle: Short Term Treatment of Hepatitis C Patients”.
  6. Invited lecture by European Association of Study of Liver Diseases (EASL) Vienna Austria on April 22nd 2006. Tot; e: “Hepatitis C Treatment in Patients with Normal Liver Function Test”.
  7. Invited Lecture of Hong Kong Society of Gastroenterology. Title: “Therapeutic Endoscopy New Trends”.
  8. Invited lecture by Turkish Society of Gastroenterology in Istanbul Turkey on October 07, 2005. Title: Variceal Bleed Management”.
  9. Invited lecture by Egyptian Society of Gastroenterology in September 2004 in Cairo, Egypt. Title: “Peptic Ulcer Disease Management”.
  10. Invited lecture at annual conference of Malaysian society of Gastroenterology in July 2004 in Kuala Lumpur, Title: “Hepatitis C Treatment New Trends”.

REFERENCES

  • Wasim Jafri (FRCP London), Associate Dean, Aga Khan University Hospital, Pakistan,
    Email: [email protected], Phone: 0092-300-2565301
  • Javed Akram (FRCP London), Vice Chancellor, Shaheed Zulifqar Ali Bhutto Medical University, Islamabad, Pakistan
    Email: [email protected], Phone: 0092-300-8450505
  • Aurangzeb Durrani (FRCP EDIN), Chair Department of Medicine, Fauji Foundation University Hospital, Rawalpindi, Pakistan
    Email: [email protected], Phone: 0092-300-5155621